Mucosal-associated invariant T-cells in pulmonary pathophysiology DOI Creative Commons

Jéssica Kamiki,

Carolina Mendonça Gorgulho, Joana R. Lérias

et al.

Current Opinion in Pulmonary Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: March 19, 2025

Purpose of review Mucosal-associated invariant T-cells (MAIT) have been associated with lung cancer and pulmonary infections. The treatment patients or infections includes host-directed therapies (HDTs). MAIT play a role in shaping the ‘milieu interne’ this addresses biology pathophysiology. Recent findings represent an attractive target for therapy malignancies are often difficult to exploit therapeutically due diversity both T-cell receptor (TCR) repertoire its ligandome. MAIT-cells restricted by major histocompatibility complex class I-related gene protein (MR1) that presents nondefined tumor-associated targets, bacterial products, vitamin drug derivates. Due their plasticity expression, able conversely switch from IFN-γ IL-17 production. Both cytokines key protective immune responses malignancies. MAIT-derived production interleukin (IL)-17/TGF-β shapes tumor micro-environment (TME), including tissue re-modelling leading fibrosis recruitment neutrophils. contribute gut-lung axis clinical improved checkpoint inhibition therapy. at crossroad HDTs targeting malignant infected cells. Clinical presentations overt inflammation, re-modeling reviewed along balance between Th1, Th2, Th9, Th17 immune-suppression Summary shape TME Drugs affect can be explored achieve results while curbing tissue-damaging responses.

Language: Английский

Mucosal-associated invariant T-cells in pulmonary pathophysiology DOI Creative Commons

Jéssica Kamiki,

Carolina Mendonça Gorgulho, Joana R. Lérias

et al.

Current Opinion in Pulmonary Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: March 19, 2025

Purpose of review Mucosal-associated invariant T-cells (MAIT) have been associated with lung cancer and pulmonary infections. The treatment patients or infections includes host-directed therapies (HDTs). MAIT play a role in shaping the ‘milieu interne’ this addresses biology pathophysiology. Recent findings represent an attractive target for therapy malignancies are often difficult to exploit therapeutically due diversity both T-cell receptor (TCR) repertoire its ligandome. MAIT-cells restricted by major histocompatibility complex class I-related gene protein (MR1) that presents nondefined tumor-associated targets, bacterial products, vitamin drug derivates. Due their plasticity expression, able conversely switch from IFN-γ IL-17 production. Both cytokines key protective immune responses malignancies. MAIT-derived production interleukin (IL)-17/TGF-β shapes tumor micro-environment (TME), including tissue re-modelling leading fibrosis recruitment neutrophils. contribute gut-lung axis clinical improved checkpoint inhibition therapy. at crossroad HDTs targeting malignant infected cells. Clinical presentations overt inflammation, re-modeling reviewed along balance between Th1, Th2, Th9, Th17 immune-suppression Summary shape TME Drugs affect can be explored achieve results while curbing tissue-damaging responses.

Language: Английский

Citations

0